SFDA Unveils Five-Year Plan To Raise Drug Supervision Standards
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA aims to raise drug quality and supervision standards over the next five years to reach international levels and to control risks associated with traditional Chinese medicines, according to Wu Zhen, deputy director of SFDA
You may also be interested in...
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7
China’s 2009 Regulatory Changes Will Affect Makers of Drugs, APIs and Devices
BEIJING - An array of regulatory and legal changes covering pharmaceuticals and medical devices in China is likely to be launched or broadened this year, including new GMP guidelines, as the country aims to upgrade supervision of the entire health care sector, according to a leading Chinese lawyer in the area of life sciences-related issues and legislation
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).